Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer

Journal of Clinical Oncology

Volumn 13, Issue 9, 1995, Pages 2324-2329

  Wiesenfeld, Martin ^b   O'Connell, Michael J ^a   Wieand, H Sam ^b   Gonchoroff, Nick J ^b   Donohue, John H ^b   Fitzgibbons Jr , Robert J ^b   Krook, James E ^b   Mailliard, James A ^b   Gerstner, James B ^b   Pazdur, Richard ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; HLA DR ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0029129603     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.9.2324     Document Type: Article

References (26)

1. Nathan CF, Murray HW, Wiebe ME, et al: Identification of interferon-γ as the lymphokine which activated human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158:670-689, 1983
2. Nathan CT, Horowitz CR, DeLaHarpe J, et al: Administration of recombinant interferon-γ to cancer patients enhances monocyte secretion of hydrogen peroxide. Proc Natl Acad Sci USA 82:8686-8690, 1985
3. Svedersky LP, Shepard HM, Spencer SA, et al: Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin-2. J Immunol 133:714-718, 1984
4. Itoh K, Shiiba K, Shimizu Y, et al: Generation of activitated HILL (AK) cells by recombinant IL-2 in collaboration with interferon-γ. J Immunol 134:3124-3129, 1985
5. Herlyn M, Guerry D, Koprowski H: Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol 134:4226-4230, 1985
6. Ball ED, Sorenson GD, Pettengill OS: Expression of myeloid and major histocompatibility antigens on small cell carcinoma of the lung cell lines analyzed by cytofluorography: Modulation by gamm-interferon. Cancer Res 46:2335-2339, 1986
7. Guyre PM, Morganelli PM, Miller R: Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. J Clin Invest 72:393-397, 1983
8. Talmadge JE, Trivble HR, Pennington RW, et al: Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice. Cancer Res 47:2563-2570, 1987
9. Rubin BY, Gupta SL: Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77:5928-5932, 1980
10. Blalock JE, Georgiades JA, Langford MP, et al: Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cell Immunol 49:390-394, 1980
11. Pfizenmaier K, Bartsch H, Scheurich P, et al: Differential gamma-interferon response of human colon carcinoma cells: Inhibition of proliferation and modulation of immunogenecity as independent effects of gamma-interferon on tumor cell growth. Cancer Res 45:3503-3509, 1985
12. Salup RR, Wiltrout RH: Treatment of adenocarcinoma of the peritoneum of mice: Chemoimmunotherapy with IL-2 stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease. Cancer Immunol Immunother 22:31-36, 1986
13. Maluish AE, Urba WJ, Longo DL, et al: The determination of an immunologically active of interferon-gamma in patients with melanoma. J Clin Oncol 6:434-445, 1988
14. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
15. Pujol JL, Gibney DJ, Su JQ, et al: Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. J Natl Cancer Inst 85:1844-1850, 1993
16. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352, 1990
17. SAS/STAT User's Guide. Version 6 ed (vol 2). Cary, NC, SAS Institute, 1990
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
20. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
21. Wilcoxon F: Individual comparisons by ranking methods. Biometrics Bull 1:80-83, 1945
22. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
23. Meyskens FL Jr, Kopecky K, Samson M, et al: A phase III trial of recombinant human interferon-gamma as adjuvant therapy of high risk malignant melanoma. Proc Am Soc Clin Oncol 10:A1010, 1991 (abstr)
24. Jett JR, Su JQ, Maksymiuk AW: Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. Proc Am Soc Clin Oncol 11:A956, 1992 (abstr)
25. O'Connell MJ, Ritts RA, Moertel CG, et al: Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9. Cancer 63:1998-2004, 1989
26. Jaffe HS, Herberman RB: Rationale for recombinant human interferon-gamma adjuvant immunotherapy for cancer. J Natl Cancer Inst 80:616-618, 1988